Trial Profile
Maraviroc and NeuroAIDS Pathogenesis
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 11 Jul 2023
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 07 Jul 2023 Results published in the AIDS
- 10 Mar 2021 Primary endpoint of Change in Neuropsychological Performance has not been met, according to results presented at the 28th Conference on Retroviruses and Opportunistic Infections.
- 10 Mar 2021 Status changed from recruiting to completed according to results presented at the 28th Conference on Retroviruses and Opportunistic Infections.